amg 330
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2015 (NCT02520427)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E activator
- Myeloid cell surface antigen CD33INHIBITOR
CD33 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- amg 330
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04478695 | Phase 1 | Sep 29, 2020 | Amgen, Merck |
| NCT02520427 | Phase 1 | Aug 31, 2015 | Amgen |
Showing 2 of 2 trials
Page 1 / 1